At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Idelalisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Assess the Efficacy and Safety of GS-1101 (CAL-101) in Patients With Relapsed or Refractory Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Idelalisib for Hodgkin Lymphoma. Completed, enrolled 25 participants across 3 sites.
Detailed Summary
This study will evaluate the efficacy and safety of idelalisib in participants with relapsed of refractory Hodgkin Lymphoma (HL). The primary objective will be to assess the overall response rate. Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg twice daily. Treatment with idelalisib will continue until tumor progression or unacceptable toxicity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartSep 2011
Primary CompletionAug 2014
TodayJul 2026
First PostedJul 13, 2011
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.0 years ago
Interventions
Idelalisibdrug
Idelalisib tablets administered orally